Current innovation activities

At chimera biotec GmbH, we continuously innovate to push the boundaries of bioanalytical research. Our current projects and developments include:

1. expansion of Imperacer® technology: We are working on the further development of our award-winning immuno-PCR technology to enable even more sensitive and precise assays. This technology combines the specificity of ELISA with the sensitivity of qPCR, resulting in an up to 1000-fold improvement in the limit of detection1.

2. new areas of application with AI: Our research focuses on the development of new AI-based assays for the detection of biomarkers in complex matrices such as blood, saliva and cerebrospinal fluid. In the future, these assays will also be used for clinical drug development.

3. collaborations and partnerships: We are proud of our collaborations with leading research institutions and pharmaceutical companies worldwide. These partnerships enable us to develop innovative solutions and test our technologies in new fields of application.

4. sustainability and efficiency: Another focus of our innovation activities is on improving the sustainability of our processes. We implement environmentally friendly methods and reduce the consumption of resources in order to minimize our ecological footprint.

5. publications and presentations: Our latest research findings and developments are regularly published in renowned scientific journals and presented at international conferences. This underlines our commitment to scientific excellence and innovation.